{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:18Z","timestamp":1784696778089,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a hematological malignancy characterized by proliferation of malignant plasma cells. UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) has been shown to promote progression in various cancers. However, its specific role in MM remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed six datasets comprising 3,117 patients from the Multiple Myeloma Research Foundation and Gene Expression Omnibus databases. The reliability of UAP1 as a prognostic predictor was also systematically evaluated. To further elucidate the specific mechanisms underlying the role of UAP1 in promoting MM progression, we performed an in-depth analysis of single-cell RNA sequencing data from 24 patients with MM. Additionally, we evaluated UAP1\u2019s therapeutic potential using two MM cell lines (RPMI-8226 and U266).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across all 3,117 patients with MM, high UAP1 expression correlated with significantly worse overall survival, event-free survival, and progression-free survival. Patients with high UAP1 expression consistently exhibited concurrent genetic abnormalities. Single-cell data suggest that UAP1 is predominantly expressed in tumor cells, is closely associated with tumor cell differentiation signatures, and shows a correlative link with the expression of immunosuppressive pathway components.\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments demonstrated that UAP1 knockdown significantly inhibited cell proliferation and cell cycle progression, enhanced apoptosis, and increased the dexamethasone sensitivity of RPMI-8226 and U266 cells. Genetic knockdown of UAP1 significantly increased the proportion of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in\n                      <jats:italic>in vitro<\/jats:italic>\n                      co-culture system with MM cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>UAP1 expression is significantly correlated with tumor differentiation, proliferation, immunosuppression, and patient prognosis, establishing it as an prognostic biomarker Regulating Malignant Biological Functions in Multiple Myeloma Cells. Our findings may guide the development of novel treatment strategies and improve clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1902414","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:42:52Z","timestamp":1784695372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["UAP1 as a prognostic biomarker regulating malignant biological functions in multiple myeloma cells"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiang","family":"Li","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, China"]},{"name":"Institute of Precision Medicine, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjian","family":"Yan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, China"]},{"name":"Institute of Precision Medicine, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Bishan Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wei","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, China"]},{"name":"Institute of Precision Medicine, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Cai","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, China"]},{"name":"Institute of Precision Medicine, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Department of Hematology, Zhangpu County Hospital","place":["Zhangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, China"]},{"name":"Institute of Precision Medicine, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-2159","article-title":"Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice","volume":"20","author":"Landgren","year":"2014","journal-title":"Clin Cancer Res: Off J Am Assoc For Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.trsl.2018.05.003","article-title":"Novel biomarkers in multiple myeloma","volume":"201","author":"Levin","year":"2018","journal-title":"Trans Res J Lab Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2018-0379","article-title":"Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey","volume":"57","author":"Wang","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/elps.201800238","article-title":"Glycosylation and metastases","volume":"40","author":"Josic","year":"2019","journal-title":"Electrophoresis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22377","article-title":"Drug resistance related to aberrant glycosylation in colorectal cancer","volume":"9","author":"Very","year":"2018","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-011-0138-5","article-title":"Gene expression of O-GlcNAc cycling enzymes in human breast cancers","volume":"12","author":"Krze\u015blak","year":"2012","journal-title":"Clin Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m111.302547","article-title":"Critical role of O-Linked \u03b2-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis","volume":"287","author":"Lynch","year":"2012","journal-title":"J Biol Chem"},{"key":"B13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/genes11070763","article-title":"Quantitative proteomics of urinary bladder cancer cell lines identify UAP1 as a potential therapeutic target","volume":"11","author":"Puttamallesh","year":"2020","journal-title":"Genes (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S282238","article-title":"Expression and bioinformatics-based functional analysis of UAP1 in lung adenocarcinoma","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03291-0","article-title":"Identification of UAP1L1 as a critical factor for prostate cancer and underlying molecular mechanism in tumorigenicity","volume":"20","author":"Wu","year":"2022","journal-title":"J Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/erc-16-0569","article-title":"Glycosylation is a global target for androgen control in prostate cancer cells","volume":"24","author":"Munkley","year":"2017","journal-title":"Endocrine-Related Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1028263","article-title":"The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.307","article-title":"UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation","volume":"34","author":"Itkonen","year":"2015","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.104713","article-title":"NSUN2-mediated m(5)C modification drives alternative splicing reprogramming and promotes multidrug resistance in anaplastic thyroid cancer through the NSUN2\/SRSF6\/UAP1 signaling axis","volume":"15","author":"Hou","year":"2025","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00165-x","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41408-022-00708-3","article-title":"Racial differences as predictors of outcomes in young patients with multiple myeloma","volume":"12","author":"Bao","year":"2022","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.3390\/ijms23147530","article-title":"Prognostic value of association of copy number alterations and cell-surface expression markers in newly diagnosed multiple myeloma patients","volume":"23","author":"Drago\u0219","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/532269a","article-title":"The tumour trail left in blood","volume":"532","author":"Chi","year":"2016","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8157","article-title":"The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma","volume":"15","author":"Zhu","year":"2018","journal-title":"Oncol Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1038\/s41467-024-52725-4","article-title":"An automated network-based tool to search for metabolic vulnerabilities in cancer","volume":"15","author":"Valc\u00e1rcel","year":"2024","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/943096","article-title":"Mechanisms and clinical applications of genome instability in multiple myeloma","volume":"2015","author":"Cagnetta","year":"2015","journal-title":"BioMed Res Int"},{"key":"B29","first-page":"489","article-title":"Risk stratification in multiple myeloma, part 1: characterization of high-risk disease","volume":"11","author":"Biran","year":"2013","journal-title":"Clin Adv Hematol Oncol H&O"},{"key":"B30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-019-0226-4","article-title":"An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q syndrome","volume":"9","author":"Sawyer","year":"2019","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1983427","article-title":"Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies","volume":"14","author":"Bisht","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3390\/cancers13030517","article-title":"Genetic analysis of multiple myeloma identifies cytogenetic alterations implicated in disease complexity and progression","volume":"13","author":"Li","year":"2021","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000181","article-title":"Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma","volume":"3","author":"Alagpulinsa","year":"2019","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","article-title":"Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages","volume":"14","author":"Cheng","year":"2024","journal-title":"Blood Cancer J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood-2018-99-114145","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01528-0","article-title":"Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations","volume":"40","author":"He","year":"2021","journal-title":"Oncogene"},{"key":"B39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41746-025-01967-7","article-title":"Machine learning analysis reveals tumor heterogeneity and stromal-immune niches in breast cancer","volume":"8","author":"Kuang","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.3390\/ijms23169124","article-title":"High IGKC-expressing intratumoral plasma cells predict response to immune checkpoint blockade","volume":"23","author":"Onieva","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114088","article-title":"IFN\u03b1-induced BST2(+) tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling","volume":"43","author":"Zheng","year":"2024","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113320","article-title":"Palmitic acid inhibits macrophage-mediated chemotherapy resistance in multiple myeloma via ALOX12 signaling","volume":"143","author":"Dong","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1038\/s41467-025-57966-5","article-title":"Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma","volume":"16","author":"Yan","year":"2025","journal-title":"Nat Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:42:56Z","timestamp":1784695376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1902414"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1902414","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1902414"}}